In this issue, Paiva and colleagues characterize the dynamics of minimal residual disease (MRD) and clinical responses during chimeric antigen receptor (CAR) T-cell therapy of relapsed/refractory multiple myeloma. Although both correlate with prolonged progression-free survival, MRD is reached faster in the bone marrow than complete response in peripheral blood; consequently, the study addresses the need for future guidelines to explore new MRD-negative definitions that are independent of the monoclonal (M) protein to overcome this limitation, particularly in clinical trials using early depth of response as an endpoint.
MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma
Blood Cancer Discov 2023;4:346–8
Ola Landgren, Dickran Kazandjian; MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma. Blood Cancer Discov 1 September 2023; 4 (5): 346–348. https://doi.org/10.1158/2643-3230.BCD-23-0134
Download citation file:
Citing articles via